N. Engl. J. Med., 377 (2017), pp. 829-838 CrossrefView in ScopusGoogle Scholar 76. A.T. Shaw, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 Ann. Oncol., 30 (2019), pp. 1121-1126...
N Engl J Med 291:866–871 PubMed CAS Google Scholar Bordier P, de Sèze S, Miravet L, Berbir N (1974) Physiopathologie de l’ostéoporose de l’adulte jeune. Sem Hop Paris 50:197–206 PubMed CAS Google Scholar Bordier PJ, Guéris J, Arnaud CJ, Rasmussen H (1975) Diagnostic ...
N. Engl. J. Med. 2017, 376, 629–640. [Google Scholar] [CrossRef] [PubMed] [Green Version] Ramalingam, S.S.; Yang, J.C.H.; Lee, C.K.; Kurata, T.; Kim, D.-W.; John, T.; Nogami, N.; Ohe, Y.; Mann, H.; Rukazenkov, Y.; et al. Osimertinib As First-Line ...
N. Engl. J. Med. 2017, 377, 829–838. [Google Scholar] [CrossRef] Pacheco, J.M.; Gao, D.; Smith, D.; Purcell, T.; Hancock, M.; Bunn, P.; Robin, T.; Liu, A.; Karam, S.; Gaspar, L.; et al. Natural History and Factors Associated with Overall Survival in Stage IV ...